Hepatosplenic candidiasis: A manifestation of chronic disseminated candidiasis

Infectious Disease Clinics of North America

Volumn 14, Issue 3, 2000, Pages 721-739

  Kontoyiannis, D P ^a   Luna, M A ^b   Samuels, B I ^c   Bodey, G P ^a  

^a Section of Infectious Diseases   (United States)

^b Department of Pathology ^*

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

BONE MARROW TRANSPLANTATION; CANDIDIASIS; CLINICAL FEATURE; DIAGNOSTIC IMAGING; HUMAN; INCIDENCE; PATHOGENESIS; PROPHYLAXIS; REVIEW;

EID: 0033831685     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70128-8     Document Type: Article

References (88)

1. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review
2. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy
3. Hepatosplenic candidiasis in patients with acute leukemia: Incidence and prognostic implications
4. Diagnostic laparoscopy in patients with acute leukemia and suspected hepatic candidiasis
5. Hepatosplenic yeast infection in patients with acute leukemia: A diagnostic problem
6. Hepatosplenic candidiasis - A contraindication to marrow transplantation?
7. Chronic systemic candidiasis in acute leukemia
8. Disseminated candidiasis in patients with acute leukemia: Two diseases?
9. Chronic systemic candidiasis
10. Hypersplenism due to disseminated candidiasis in a patient with acute leukemia
11. Fungal infections complicating acute leukemia
12. Hematogenous and major organ candidiasis
13. Definitions of Candida infections
14. Systemic chronic candidiasis following typhilitis caused by Candida albicans
15. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: The pathogenetic role of the antileukemic regimen
16. Hepatosplenic candidiasis in children with cancer. Three cases in leukemic children and a literature review
17. Distribution and activity of amphotericin B in humans
18. Risk factors for hepatosplenic abscesses in patients with acute leukemia receiving empiric azole treatment
19. The role of the gastrointestinal tract in hematogenous candidiasis: From the laboratory to the bedside
20. Gastrointestinal and systemic candidosis in immunocompromised mice
21. An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy
22. Hepatosplenic candidiasis in patients with acute leukemia: What is the optimum prophylaxis following subsequent chemotherapy
23. International conference for the development of a consensus on the management and prevention of severe candidal infections
24. Detection and identification of fungal pathogens in blood by using molecular probes
25. Causes of remission induction failure in acute myelogenous leukemia
26. Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients
27. Comparison of interferon-γ, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens
28. Antifungal agents: Chemotherapeutic targets and immunologic strategies
29. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients
30. Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: A case report
31. Ultrasound evaluation of hepatic and splenic microabscesses in the immunocompromised patient: Sonographic patterns, differential diagnosis, and follow-up
32. Hepatic candidiasis: An increasing problem in immucompromised patients
33. Treatment of hepatosplenic candidiasis with liposomal amphotericin B in a patient with acute leukemia: A case report of the experience of use of liposomal amphotericin B
34. Diagnosis and treatment of splenic fungal abscesses in the immune-suppressed patient
35. Fungal splenic abscess
36. Candida hepatitis: Histopathologic diagnosis
37. Candida splenic abscess in the absence of obvious immunodeficiency
38. Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: Value of computer assisted serial ultrasound documentation
39. Safe and effective prophylaxis of chronic disseminated candidiasis (CDC) and pulmonary infiltrations in acute leukemia patients (AL) with intensive low-dose I.V. amphotericin B (ld AMB) - A prospective trial
40. Surprising long-term, leukemia-free survival in patients with hepatosplenic candidiasis receiving minimal antileukemic therapy
41. Successful peritransplant therapy in children with active hepatosplenic candidiasis
42. Hepatosplenic candidiasis: Successful treatment with fluconazole
43. Chronic mucocutaneous candidiasis
44. Recombinant interferon-γ enhances resistance to acute disseminated Candida albicans infection in mice
45. Moniliasis in acute leukemia
46. The spectrum of hepatic candidiasis
47. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B
48. Histologic identification and pathologic patterns of disease caused by Candida
49. Systemic candidiasis in cancer patients
50. Hepatic abscess in cancer patients. Characterization and management
51. Blastoschizomyces capitatus: An emerging cause of invasive fungal disease in leukemia patients
52. Successful bone marrow transplantation in patients with previous invasive fungal infections: Report of four cases
53. Fungemia in the immunocompromised host
54. Fungal infection in acute leukemia
55. Respiratory alkalosis with abdominal pain heralding Candida hepatitis. Occurrence in patients with acute leukemia in remission
56. Fungal abscess
57. Hepatosplenic candidiasis: Wheels within wheels
58. Hepatic lesions of chronic disseminated candidiasis may become invisible during neutropenia
59. The impact of changing epidemiology of fungal infections in the 1990's
60. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group
61. Interferon gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia
62. Clinical and immunological study of 2 cases of systemic candidiasis
63. A Th1-Th2-like switch in candidiasis: New perspectives for therapy
64. Hypersplenism due to fungal infection of spleen in a successfully treated patient with Hodgkin's disease
65. Increased serum concentrations of interleukin-10 in patients with hepatosplenic candidiasis
66. Fungal liver infection in marrow transplant recipients: Prevalence at autopsy, predisposing factors, and clinical features
67. Hepatosplenic candidiasis in patients with acute leukemia: Increasingly encountered complication
68. Effect of ketaconazole, itraconazole, and fluconazole on the gastrointestinal colonization of mice by C. albicans
69. Radiologic features of Candida infections
70. Hepatosplenic fungal disease: Diagnostic accuracy and spectrum of appearances on MR imaging
71. Detection of acute and treated lesions of hepatosplenic candidiasis: Comparison of dynamic contrast-enhanced CT and MR imaging
72. Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B
73. Focal hepatic candidiasis: A distinct clinical variant of candidiasis in immunocompromised patients
74. Hepatic candidiasis in cancer patients: The evolving picture of the syndrome
75. Evaluation of single drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia
76. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis
77. Candidal splenic abscesses complicating acute leukemia of childhood treated by splenectomy
78. Lipid formulations of amphotericin B: Recent developments in improving the therapeutic index of a gold standard
79. Experimental gastrointestinal and disseminated candidiasis in immunocompromised animals
80. Effects of preventive, early and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis
81. Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts
82. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
83. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
84. Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum D-arabinitol
85. Laboratory diagnosis of candidiasis
86. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis
87. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia
88. High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia